Seeking Alpha

Navidea Biopharmaceuticals falls as Aegis cuts target

Shares of Navidea Biopharmaceuticals (NAVB -4.3%) trade lower out of the gate.

Behind the move looks to be Aegis, where, according to market chatter, analysts have cut their price target.

Reminder: Q3 Lymphoseek sales were $144K.

In other company news, NAVB says it will collaborate with the University of San Francisco "on a clinical study to evaluate, for the first time, the use and performance of technetiumlabeled tilmanocept in patients with Kaposi Sarcoma." (PR)

From other sites
Comments (3)
  • oneotherfool
    , contributor
    Comments (304) | Send Message
    Sorry SA, but are we now quoting tweets just like that?


    Are we not going to try to find the new price target? What was the older price target? How much did they cut it by? 10%, 20% 50%?....


    I'm sorry but none of this is meaningful information cut and pasted from a tweet like that.
    13 Nov 2013, 10:18 AM Reply Like
  • oneotherfool
    , contributor
    Comments (304) | Send Message
    Here's a link.



    Lowers price target from $3 to $2. It's still a >30% from here. Previous PT was at a whopping 100%.


    Makes the call look smart for the next 12-month. If it does exceed $2 any time soon, he can always "upgrade." as he pointed out by saying "would look for evidence of accelerating revenues before becoming more bullish on Navidea."
    13 Nov 2013, 11:13 AM Reply Like
  • pjg69ny
    , contributor
    Comments (255) | Send Message
    either way this stock is horrendous
    13 Nov 2013, 12:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs